News & Press Releases

Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.  

Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.

Member Jacob Hupart was quoted in a Responsible Investor article about a lawsuit challenging the SEC’s pullback from its long standing “no action” review process for shareholder proposals. In the article, Jacob addresses the legal hurdles facing the plaintiffs as they seek to frame the SEC’s policy shift as actionable under the Administrative Procedure Act.

Mintz represented Swarmer, Inc (Nasdaq: SWMR), a defense technology company specializing in drone autonomy software, in its initial public offering on the Nasdaq Capital Market. 

Mintz represented Sixth Street in connection with a $1.3 billion financing – alongside co-investor Blackstone Credit & Insurance – in support of the combination of Paratek Pharmaceuticals (Paratek) and Radius Health (Radius), creating a scaled, multi‑product specialty pharmaceutical company backed by B‑FLEXION Life Sciences.  

Of Counsel Michelle Capezza was quoted in a Fiduciary News article analyzing a Supreme Court case that could redefine ERISA litigation standards by requiring plaintiffs to plead a “meaningful benchmark” when alleging imprudent retirement plan investments. Her comments address how a potential ruling may affect fiduciary decision-making, particularly when plan committees consider alternative or illiquid investment strategies.